Company Named After Medieval German Hero Wants Drug Import License
Published Date: 11/26/2025
Notice
Summary
Siegfried Grafton, Inc. wants to become an official importer of certain controlled substances like marijuana and gamma hydroxybutyric acid. People and companies involved can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances enter the U.S., but no costs or fees are mentioned yet.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Application to Import Schedule I Substances
Siegfried Grafton, Inc. applied on September 1, 2025 to be a federal importer for the Schedule I substances gamma hydroxybutyric acid (GHB), marihuana extract, marihuana, MDMA (3,4-methylenedioxymethamphetamine), and dimethyltryptamine (DMT). If registered, the company would be authorized to import those substances only for analytical testing or distribution. Interested parties may submit comments or request a hearing by December 26, 2025.
Import Restriction: No Finished Dosage Forms
The DEA notice states that any importer registration will not authorize the import of Food and Drug Administration (FDA)-approved or non-approved finished dosage forms for commercial sale. That means import permission would be limited to non-finished forms (e.g., bulk material) and not permit bringing finished commercial drug products into the U.S.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-21177, Importer of Controlled Substances Application: Halo Pharmaceutical Inc.
Halo Pharmaceutical Inc. wants to become an official importer of certain controlled substances, including psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances enter the U.S., so keep an eye on the deadline to have your say!
Next: 2025-21179, Importer of Controlled Substances Application: Caligor Coghlan Pharma Services
Caligor Coghlan Pharma Services wants to become an official importer of certain controlled substances, including some powerful drugs like LSD. People and companies involved with these drugs can share their thoughts or ask for a hearing by December 26, 2025. This move could impact how these substances are brought into the U.S., but no costs or fees are mentioned yet.